

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



Usuf, E; Bojang, A; Camara, B; Jagne, I; Oluwalana, C; Bottomley, C; D'Alessandro, U; Roca, A (2017) Maternal pneumococcal nasopharyngeal carriage and risk factors for neonatal carriage following the introduction of Pneumococcal Conjugate Vaccines in The Gambia. *Clinical microbiology and infection*. ISSN 1198-743X DOI: <https://doi.org/10.1016/j.cmi.2017.07.018>

Downloaded from: <http://researchonline.lshtm.ac.uk/4155537/>

DOI: [10.1016/j.cmi.2017.07.018](https://doi.org/10.1016/j.cmi.2017.07.018)

#### Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>



Contents lists available at ScienceDirect

## Clinical Microbiology and Infection

journal homepage: [www.clinicalmicrobiologyandinfection.com](http://www.clinicalmicrobiologyandinfection.com)

## Original article

## Maternal pneumococcal nasopharyngeal carriage and risk factors for neonatal carriage after the introduction of pneumococcal conjugate vaccines in The Gambia

E. Usuf<sup>1,2,\*</sup>, A. Bojang<sup>1</sup>, B. Camara<sup>1</sup>, I. Jagne<sup>1</sup>, C. Oluwalana<sup>1</sup>, C. Bottomley<sup>2</sup>, U. D'Alessandro<sup>1,2,3</sup>, A. Roca<sup>1,4</sup><sup>1</sup> Medical Research Council Unit, Gambia<sup>2</sup> Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom<sup>3</sup> Institute of Tropical Medicine, Antwerp, Belgium<sup>4</sup> Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom

## ARTICLE INFO

## Article history:

Received 20 March 2017

Received in revised form

15 July 2017

Accepted 19 July 2017

Available online xxx

Editor: Dr A. Huttner

## Keywords:

Factors

Maternal

Nasopharyngeal

Neonatal

Pneumococcus

Risk

Transmission

Vertical

## ABSTRACT

**Objectives:** Pneumococcal nasopharyngeal carriage occurs early in life. However, the role of vertical transmission is not well understood. The aims of this study were to describe carriage among mothers and their newborns, and to assess for risk factors for neonatal carriage.

**Methods:** In a nested retrospective cohort study, we analysed data from the control arm of a randomized controlled trial conducted in The Gambia 2 to 3 years after introduction of pneumococcal conjugate vaccine (PCV) 13. Nasopharyngeal swabs were collected from 374 women and their newborns on the day of delivery, then 3, 6, 14 and 28 days later. Pneumococci were isolated and serotyped using conventional microbiologic methods.

**Results:** Carriage increased from 0.3% (1/373) at birth to 37.2% (139/374) at day 28 ( $p < 0.001$ ) among neonates and from 17.1% (64/374) to 24.3% (91/374) ( $p 0.015$ ) among women. In both groups, PCV13 vaccine-type (VT) serotypes accounted for approximately one-third of the pneumococcal isolates, with serotype 19A being the most common VT. Maternal carriage (adjusted odds ratio (OR) = 2.82; 95% confidence interval (CI), 1.77–4.80), living with other children in the household (adjusted OR = 4.06; 95% CI, 1.90–8.86) and dry season (OR = 1.98; 95% CI, 1.15–3.43) were risk factors for neonatal carriage. Over half (62.6%) of the neonatal carriage was attributable to living with other children in the same household.

**Conclusions:** Three years after the introduction of PCV in The Gambia, newborns are still rapidly colonized with pneumococcus, including PCV13 VT. Current strategies for pneumococcal control in Africa do not protect this age group beyond the herd effect. **E. Usuf, Clin Microbiol Infect 2017;■:1**

© 2017 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

*Streptococcus pneumoniae* is a leading cause of morbidity and mortality in children under 2 years of age [1,2]. Generally, invasive pneumococcal disease (IPD) peaks in the second year of life in developed countries and in the first year of life in sub-Saharan Africa [3,4]. Nevertheless, a substantial burden of neonatal IPD has been reported across different regions worldwide, although

data are lacking in the least developed countries [5–10]. In a recent systematic review, the global pooled neonatal IPD was estimated at 36 per 100 000 live births (95% confidence interval (CI), 20.0–64.7) [5]. From one study in The Gambia, it was estimated as 369.5 per 100 000 (95% CI, 119.2–1138.5) [3,5].

Pneumococcal conjugate vaccines (PCVs) are effective against IPD and nasopharyngeal carriage of vaccine serotypes (VT). The latter is important because carriage is a preliminary step towards disease and a measure of community transmission. The introduction of PCV has been shown to reduce acquisition of VT nasopharyngeal carriage among both vaccinated [11] and unvaccinated individuals [12]. However, it has also been shown to increase non-

\* Corresponding author. E. Usuf, Medical Research Council Unit, PO Box 273, Banjul, Gambia.

E-mail address: [eusuf@mrc.gm](mailto:eusuf@mrc.gm) (E. Usuf).

<http://dx.doi.org/10.1016/j.cmi.2017.07.018>

1198-743X/© 2017 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

vaccine-type carriage such that the overall carriage prevalence remains similar [11].

Since 2009, three formulations of PCV targeting pneumococcal serotypes most commonly associated with IPD worldwide have been introduced into routine vaccination in sub-Saharan Africa, first PCV7, then PCV10 and PCV13. Although two randomized trials in Kenya and Papua New Guinea showed that PCVs are immunogenic and well tolerated when given at birth [13,14], the World Health Organization (WHO) recommends vaccination with PCVs from 6 weeks of age [15]. This means newborns until 6 weeks of age are only protected through indirect effects (i.e. maternal antibodies and herd effect) [16–18]. New strategies are required to reduce early infection and to minimize its long-term effects such as growth impairment and neurologic sequelae [19–21].

Risk factors for pneumococcal nasopharyngeal carriage are well known for African children [22–25] but not for newborns. In this study, we assessed the prevalence of pneumococcal carriage among women and their newborns in The Gambia and analyzed risk factors for neonatal carriage after the implementation of PCV through an expanded program on immunization.

## Materials and Methods

### Study site

The study was conducted at the Jammeh Foundation for Peace, a public health facility in Western Gambia. PCV7 was introduced in The Gambia in August 2009 and was replaced by PCV13 in May 2011. Coverage of two or more doses of PCV13 before 12 months of age was 94% among rural Gambian children born in the second half of 2013 [26].

### Study design

This was a retrospective nested cohort study. The study cohort comprised mother–newborn pairs included in the placebo arm of a phase 3, double-blind, placebo-controlled, randomized trial in which women in labour were randomized to receive a single dose of 2 g of oral azithromycin or placebo (292.7 mg pregelatinized starch, 881.8 mg dibasic calcium phosphate and 11.5 mg magnesium stearate coated with 18 mg Opadry). Study women aged 18 to 45 years were recruited between April 2013 and April 2014 when attending prenatal clinic.

Nasopharyngeal swabs (NPS) were collected from mothers and their newborns during the 28 days of active follow-up. An NPS was collected from women in labour and from newborns within 6 hours of birth. Additional maternal and newborn NPS were collected at days 3, 6, 14 and 28 during household visits conducted by study nurses and field workers. Sample collection was discontinued if participants received antibiotics as part of standard care.

Epidemiologic data including demographic and other risk factor data were collected by trained field staff using questionnaires.

### Sample collection

All NPS were collected in accordance with the WHO protocol for detecting *S. pneumoniae* in the upper respiratory tract [27] and as described previously [28].

### Bacterial Isolation

Stored NPS were plated on appropriate agar for selective isolation of *S. pneumoniae* and *Staphylococcus aureus* [28]. All pneumococcal isolates were serotyped by using the latex agglutination test (Statens Serum Institute, Copenhagen, Denmark) [29].

### Data management and statistical analysis

All data were double entered into Openclinica and analysed by Stata 14 (StataCorp, College Station, TX, USA). The analysis was restricted to mothers and newborns in the placebo arm of the trial that were not missing day 28 carriage data.

The prevalence of PCV13 VT carriage (i.e. carriage of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F or 23F) and non-vaccine-type carriage was calculated for 0, 3, 6 and 14 days after birth where the latter included nontypeable isolates. We estimated the proportion of concordant pairs, defined as the proportion of mother–newborn carrier pairs where both mother and newborn carried the same serotype, either concurrently or at different times, during the neonatal period. The association between maternal carriage—defined as carriage at any time during the neonatal period—and neonatal carriage at day 28 was investigated by logistic regression. The following potential confounders were selected *a priori* for inclusion in the model [30]: birth weight, other children in the household, mother's age, mother's education and season.

The association between other children living in the household and neonatal carriage at day 28 was also investigated. The potential confounders listed above were included in this second model, except for 'other children in the household,' because this variable was already included as the exposure of interest. The model did not include maternal carriage because this may be on the causal pathway.

A similar analysis was conducted for the association between maternal carriage at day 14 and acquisition of carriage in the newborn between day 6 and day 14—i.e. carriage of any serotype at day 14 among noncarriers at day 6, and for the association between neonatal carriage at day 14 and acquisition of carriage in the mother over the same period.

The percentage of neonatal carriage attributable to each risk factor—i.e. maternal carriage and living with other children, the population-attributable fraction—was calculated using the 'punaf' command in Stata [31].

### Ethical approval

The trial was approved by the joint Medical Research Council Group–Gambia Government Ethics Committee ([ClinicalTrials.gov](http://ClinicalTrials.gov) NCT01800942).

## Results

### Characteristics of mothers and newborns

There were 417 mother–newborn pairs in the placebo arm of the trial, and 374 (89.7%) were included in the analysis. As there were four sets of twins, only 370 women were sampled. The median age of the mothers was 26 years (interquartile range, 22–30 years). Approximately half of the women had less than 1 year of any schooling (184/359, 51.2%). Forty-seven percent (173/367) of newborns were girls. The median birth weight was 3.1 kg (interquartile range, 2.9–3.4 kg), and 22 (5.9%) of 373 were low birth weight (<2.5 kg). All the newborns were breastfed; only seven were not exclusively breastfed.

### Maternal and newborn pneumococcal nasopharyngeal carriage

Among the mothers, carriage increased from 17.1% to 24.3% ( $p = 0.015$ ) between days 0 and 28, and among newborns it increased from 0.3% to 37.2% ( $p < 0.001$ ) (Fig. 1). PCV13 VT represented approximately one-third (28.2%) of all pneumococci isolates, 27.1%




Fig. 1. Pneumococcal nasopharyngeal carriage in mothers and newborns. VT, vaccine type; NVT, non-vaccine type.

(99/366) for mothers and 29.9% (70/234) for newborns (Fig. 2). Serotype 19A was the most common serotype among newborns and the second most common among mothers. Nontypeable pneumococci were also common among both mothers (36/366, 9.8%) and newborns (14/234, 6.0%). Only five mothers and seven newborns carried multiple serotypes during the study period.

In 76 (20.3%) of the mother–newborn pairs, the mother was a carrier but the newborn was not, and in 56 pairs (15.0%) the newborn was a carrier but the mother was not. Among the 97 pairs (25.9%) where both the mother and newborn were carriers, 47 (48.5%; 95% CI, 38.2–58.9) were concordant (i.e. carried the same serotype). Of these, 31.9% (15/47) pairs were concordant with VT;




Fig. 2. Serotypes isolated from mothers and their babies during neonatal period. (A) Serotypes among mothers. (B) Serotypes among newborns.




Fig. 3. Frequency of concordant serotypes among mother–newborn pairs. Red bars, vaccine type serotypes; blue bars, non-vaccine type.

19F was the most common, at 8.5% (4/47). There were four concordant cases among those who did not have other children in the household (serotypes 9N, 19F, 21 and 47) (Fig. 3).

#### Risk factors for pneumococcal nasopharyngeal carriage in newborns

In the univariable analysis, the prevalence of carriage at day 28 was higher in newborns born during the dry season (odds ratio (OR) = 1.84; 95% CI, 1.13–2.99), those whose mothers were carriers (OR = 2.63; 95% CI, 1.71–4.05), those living with other children (OR = 4.62; 95% CI, 2.28–9.36) and those with normal birth weight (OR = 4.00; 95% CI, 1.16–13.79) (Table 1).

Maternal carriage remained a risk factor for neonatal carriage after adjusting for birth weight, other children in household, mother's age, mother's education and season (adjusted OR = 2.69; 95% CI, 1.68–4.30;  $p < 0.001$ ). Living with other children in the household after adjusting for birth weight, mother's age, mother's education and season was also a risk factor for neonatal carriage at

Table 1  
Risk factors for neonatal nasopharyngeal pneumococcal carriage at day 28 (N = 374)

Characteristic	Variable	Carriage, n (%)	Total (N)	Crude		Adjusted OR	p
				OR (95% CI)	p		
<b>Newborn</b>							
Gender	Female	67 (38.7)	173	1			
	Male	72 (37.1)	194	0.93 (0.61–1.42)	0.750		
Birth weight	<2.5 kg	3 (13.6)	22	1		1	
	≥2.5 kg	136 (38.8)	351	4.00 (1.16–13.79)	0.028	3.461 (0.91–13.11)	0.068
Gestational age	<37 weeks	85 (38.8)	219	1			
	≥37 weeks	54 (35.5)	152	0.87 (0.56–1.33)	0.520		
<i>Staphylococcus aureus</i> carriage at day 28	No	87 (36.0)	242	1			
	Yes	52 (39.4)	132	1.15 (0.75–1.79)	0.510		
<b>Maternal</b>							
Mother carrier <i>Streptococcus pneumoniae</i> at day 28	No	94 (33.2)	283	1			
	Yes	45 (49.5)	91	1.97 (1.21–3.18)	0.006		
Mother carrier day 14 and carrier day 28	No	117 (35.1)	333	1			
	Yes	22 (53.7)	41	2.13 (1.11–4.11)	0.023		
Mother carrier day 28, noncarrier day 14	No	118 (36.2)	326	1			
	Yes	21 (43.8)	48	1.37 (0.74–2.53)	0.313		
Mother carrier any time during neonatal period	No	54 (26.9)	201	1		1	
	Yes	85 (49.1)	173	2.63 (1.71–4.05)	<0.001	2.82 (1.77–4.80)	<0.001
Mother <i>S. aureus</i> carrier at day 28	No	99 (36.0)	275	1			
	Yes	40 (40.4)	99	1.21 (0.75–1.93)	0.437		
Mother's age	<25 years	72 (34.0)	212	1			
	≥25 years	67 (41.6)	161	1.39 (0.91–2.11)	0.131		
Ethnicity	Mandinka	54 (32.7)	165	1			
	Wolof	17 (40.5)	42	1.40 (0.70–2.81)			
	Jola	22 (42.3)	52	1.51 (0.80–2.86)			
	Fula	25 (44.6)	56	1.66 (0.89–3.08)			
Mother's years of schooling	Others	21 (35.6)	59	1.13 (0.61–2.12)			
	None or <1 year	74 (40.2)	184	1			
Mother can read	≥1 year	59 (33.7)	175	0.76 (0.49–1.16)	0.203		
	No	99 (40.4)	245	1			
Mother can write	Yes	40 (31.0)	129	0.66 (0.42–1.04)	0.075		
	No	98 (40.2)	244	1			
Household	Yes	41 (31.5)	130	0.69 (0.44–1.08)	0.101		
	No	126 (36.7)	343	1			
Smoker in house	Yes	13 (41.9)	31	1.24 (0.59–2.62)	0.567		
	No	82 (40.4)	203	1			
Who bathes child	Mother	53 (32.9)	161	0.72 (0.47–1.11)	0.143		
	Other	10 (13.9)	72	1		1	
Other children in household	Yes	129 (42.7)	302	4.62 (2.28–9.36)	<0.001	4.06 (1.90–8.86) <sup>a</sup>	<0.001
	No	62 (34.3)	181	1			
Number of children at school	≥1	76 (39.8)	191	1.26 (0.83–1.93)	0.270		
	0	62 (34.3)	181	1			
<b>Other factors</b>							
Season	Rainy	30 (27.5)	109	1		1	
	Dry	109 (41.1)	265	1.84 (1.13–2.99)	0.014	1.98 (1.15–3.43)	0.014

CI, confidence interval; OR, odds ratio.

Adjusted OR adjusted for birth weight, other children living in household, mother's age, mother's education and season.

<sup>a</sup> Model did not include maternal carriage, thought to be on the causal pathway.

day 28 (adjusted OR = 3.40; 95% CI, 1.55–7.50, *p* 0.002). The fraction of neonatal carriage at day 28 attributed to maternal carriage was 10.6% (95% CI, 2.5–18.0), and the fraction attributable to living with other children in the household was 62.6% (95% CI, 35.4–78.4).

Mothers who were not carriers at day 6 had a higher carriage at day 14 if their baby was a carrier at day 14, although this was not statistically significant (adjusted OR = 1.54; 95% CI, 0.75–3.18; *p* 0.326). Newborns who were not carriers at day 6 had a higher risk of being a carrier at day 14 if their mother was a carrier at day 14 (adjusted OR = 1.88; 95% CI, 1.01–3.48; *p* 0.045).

## Discussion

The prevalence of pneumococcal nasopharyngeal carriage among Gambian women and their newborns during the 4 weeks after delivery was high. Although the study was conducted 2 to 3 years after routine PCV13 introduction (and 4 to 5 years after PCV7 introduction), one-third of the serotypes identified were PCV13 VT. Both maternal carriage and living with other children in the household were risk factors for neonatal carriage, with the latter accounting for almost two-thirds of neonatal carriage.

The prevalence of neonatal colonization (37.2%) was lower than in two previous studies conducted before PCV introduction in The Gambia. In both these studies, the prevalence was more than 50% by the age of 4 weeks [17,32]. One difference between these previous studies and ours is that the former were conducted in rural areas where most deliveries occurred at home, while the latter was conducted in a periurban health facility.

A striking finding in our study was the sharp increase in carriage in both mothers and newborns between days 6 and 14 (carriage in newborns continued to increase up to day 28). In The Gambia, newborns are given their name at day 7 after birth in a naming ceremony, and this is usually preceded by cooking and people moving around the compound. This may increase pneumococcal transmission during this period as people visit the mother and newborn. In line with our results, a previous longitudinal study in rural Gambia showed that maternal carriage doubled within the first 2 months after delivery and remained high until the end of 1 year, when follow-up ended [33].

In our study, a third of the isolates were PCV13 VT, a lower proportion than that observed in a pre-PCV study conducted in rural Gambia where 50% of isolates were PCV13 VT. Serotype 19A, included in PCV13 but not in PCV7, was one of the most common VT serotypes, representing approximately 9% of pneumococcal carriage. By comparison, in the United States, serotype 19A significantly decreased after PCV13 introduction, although it still contributed up to 5% of the total *S. pneumoniae* carriage 5 years later [34]. In South Africa, prevalence of serotype 19A in children was 2.7% two years after the introduction of PCV13 [35].

The prevalence of PCV13 VT among mothers in our study was 8.8% and among newborns was 11.8%. These estimates are consistent with the predictions of a mathematical model of carriage in The Gambia, which predicted that PCV13 VT carriage would decline to 7% three years after PCV13 [36]. Although it appears that VT have decreased, Gambian newborn babies are still unprotected against VT during a period when they are at high risk of infection, since the first dose in the Expanded Program on Immunization (EPI) schedule is given at 8 weeks of age in the national EPI.

Between 6% and 10% of isolates were not typeable, similar to earlier studies conducted after PCV [18,37], but different from the prevaccine estimates in The Gambia, which were about 2% [38]. An increase in nontypeable isolates after PCV has been related to serotypeable isolates that do not express their capsule [18].

Serotype concordance for mother–newborn carrier pairs was close to 50%. In Malawi, a lower concordance (9.1%) between mothers and their newborns was reported, but these infants were older (<3 months of age) and therefore more likely to acquire carriage from sources other than the mother [39]. The high concordance appears to be at odds with the low proportion of neonatal carriage attributable to maternal carriage (population-attributable fraction), observed both in our study (10.6%) and in a previous study in rural Gambia (9.5%) [33]. This discrepancy may suggest that other children in the household may be transmitting to both mothers and newborns. Compared to the proportion of neonatal carriage attributable to maternal carriage, the proportion attributable to living with other children was considerably higher (62.6%). This was both because the OR was higher and because carriage was more common in children than in mothers.

Although the association between other children living in the household and neonatal carriage was strong and has been observed in Asia and other parts of Africa [35,40–42], we cannot exclude the notion that it is due to differences in socioeconomic status between households with a small and large number of children.

Other factors associated with neonatal carriage were low birth weight and dry season. The decreased carriage risk with low birth weight was a surprising finding, though it has been reported in Indian and Dutch babies (<https://repub.eur.nl/pub/22193/>) [19] and may be due to behavioural factors, as these children are perhaps less exposed to other family members. The association with season was previously shown among older children in rural Gambia, and we therefore would expect the same pattern with neonates. Such an association may reflect greater social mixing during the dry season, when villagers spend less time on their farms [43].

Our analysis has a number of limitations. Firstly, the rates of carriage may have been underestimated because the women and their newborns received relatively more medical attention than the general local population during the study period. In addition, only healthy mothers and newborns were recruited into the study. Secondly, the analysis was restricted to mother–newborn pairs with both swabbed at day 28. Thirdly, the risk factors tested were not exhaustive. In particular, we did not assess for the presence of upper respiratory tract infections, which has been shown to increase the risk of carriage [44], and we were unable to explore the role of breastfeeding because the newborns were all breastfed. The effect of maternal carriage on newborn carriage may have been diluted, as about half of the mother–newborn pairs were discordant. Fourthly, we did not use molecular techniques [45], so we may have missed low-density carriers and cases of multiple carriage.

## Conclusions

Gambian newborns are rapidly colonized by pneumococcus during the first month of life, and current strategies for pneumococcal control in Africa do not protect this age group beyond the herd effect. More than 2 years after PCV13 introduction (4 years after PCV7 introduction), PCV13 VT are still transmitted in the community, representing one-third of strains isolated from neonatal and maternal nasopharyngeal carriage. Living with other children was the major risk factor for neonatal carriage.

## Acknowledgements

We are grateful to the mothers and their newborns who participated in the original trial. Special thanks to the study team who conducted the original study, particularly the nurses, led by E.



Sabally; the field staff, led by P. Nasso; the head of data management, B. L. Dondeh; the data entry manager, M. Sowe; and the project support officer, I. Foon. We also appreciate the collaboration with the Jammeh Foundation for Peace Hospital.

### Transparency Declaration

The original trial was jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement (MR/J010391/1) and is also part of the EDCTP2 programme supported by the European Union. This ancillary study was part of EU's funded work under a West Africa Fellowship, a joint initiative of MRC/London School of Hygiene and Tropical Medicine (LSHTM). EU is funded under a West Africa Fellowship a joint MRC/LSHTM initiative. EU does consultancy for the GSK Malaria RTSS team. All other authors report no conflicts of interest relevant to this article.

### Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.cmi.2017.07.018>.

### References

- [1] O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates. *Lancet* 2009;374(9693):893–902.
- [2] Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. *Lancet* 2013;381(9875):1405–16.
- [3] O'Dempsey TM, Lloyd-Evans TF, Baldeh N, Laurence I, Secka OBE, Greenwood BM. Pneumococcal disease among children in a rural area of West Africa. *Pediatr Infect Dis J* 1996;15:431–7.
- [4] Zangwill KM, Vadheim CM, Vannier AM, Hemenway LS, Greenberg DP, Ward JJ. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. *J Infect Dis* 1996;174:752–9.
- [5] Billings ME, Deloria-Knoll M, O'Brien KL. Global burden of neonatal invasive pneumococcal disease: a systematic review and meta-analysis. *Pediatr Infect Dis J* 2016;35:172–9.
- [6] Mulholland EK, Ogunlesi OO, Adegbola RA, Weber M, Sam BE, Palmer A, et al. Etiology of serious infections in young Gambian infants. *Pediatr Infect Dis J* 1999;18(10 Suppl):S35–41.
- [7] Muhe L, Tilahun M, Lulseged S, Kebede S, Enaro D, Ringertz S, et al. Etiology of pneumonia, sepsis and meningitis in infants younger than three months of age in Ethiopia. *Pediatr Infect Dis J* 1999;18(10 Suppl):S56–61.
- [8] Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, Mwarumba S, et al. Bacteremia among children admitted to a rural hospital in Kenya. *N Engl J Med* 2005;352:39–47.
- [9] Campbell JD, Kotloff KL, Sow SO, Tapia M, Keita MM, Keita T, et al. Invasive pneumococcal infections among hospitalized children in Bamako, Mali. *Pediatr Infect Dis J* 2004;23:642–9.
- [10] Sigauque B, Roca A, Mandomando I, Morais L, Quinto L, Sacarlal J, et al. Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. *Pediatr Infect Dis J* 2009;28:108–13.
- [11] Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. *Vaccine* 2013;32:133–45.
- [12] O'Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, Reid R, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. *J Infect Dis* 2007;196:1211–20.
- [13] Scott JA, Ojal J, Ashton L, Muhoro A, Burbidge P, Goldblatt D. Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. *Clin Infect Dis* 2011;53:663–70.
- [14] Pomat WS, van den Biggelaar AH, Phuanukoonnon S, Francis J, Jacoby P, Siba PM, et al. Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial. *PLoS One* 2013;8:e56698.
- [15] World Health Organization. Pneumococcal vaccines WHO position paper—2012—recommendations. *Vaccine* 2012;30:4717–8.
- [16] Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. *JAMA* 2006;295:1668–74.
- [17] Egere U, Townend J, Roca A, Akinsanya A, Bojang A, Nsempong D, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal carriage in newborns in rural Gambia: a randomised controlled trial. *PLoS One* 2012;7:e49143.
- [18] Roca A, Bojang A, Bottomley C, Gladstone RA, Adetifa JU, Egere U, et al. Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the expanded programme of immunization in The Gambia. *Vaccine* 2015;33:7144–51.
- [19] Coles CL, Rahmattullah L, Kanungo R, Katz J, Sandiford D, Devi S, et al. Pneumococcal carriage at age 2 months is associated with growth deficits at age 6 months among infants in South India. *J Nutr* 2012;142:1088–94.
- [20] Goetghebuer T, West TE, Wermenbol V, Cadbury AL, Milligan P, Lloyd-Evans N, et al. Outcome of meningitis caused by *Streptococcus pneumoniae* and *Haemophilus influenzae* type b in children in The Gambia. *Trop Med Int Health* 2000;5:207–13.
- [21] Edmond K, Dieye Y, Griffiths UK, Fleming J, Ba O, Diallo N, et al. Prospective cohort study of disabling sequelae and quality of life in children with bacterial meningitis in urban Senegal. *Pediatr Infect Dis J* 2010;29:1023–9.
- [22] Hill PC, Townend J, Antonio M, Akinsanya B, Ebruke C, Lahai G, et al. Transmission of *Streptococcus pneumoniae* in rural Gambian villages: a longitudinal study. *Clin Infect Dis* 2010;50:1468–76.
- [23] Lloyd-Evans N, O'Dempsey TJ, Baldeh I, Secka O, Demba E, Todd JE, et al. Nasopharyngeal carriage of pneumococci in Gambian children and in their families. *Pediatr Infect Dis J* 1996;15:866–71.
- [24] Regev-Yochay G, Raz M, Dagan R, Porat N, Shainberg B, Pinco E, et al. Nasopharyngeal carriage of *Streptococcus pneumoniae* by adults and children in community and family settings. *Clin Infect Dis* 2004;38:632–9.
- [25] Cheung YB, Zaman SM, Nsempong ED, Van Beneden CA, Adegbola RA, Greenwood B, et al. Nasopharyngeal carriage of *Streptococcus pneumoniae* in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings. *Pediatr Infect Dis J* 2009;28:990–5.
- [26] Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D, et al. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study. *Lancet Infect Dis* 2016;16:703–11.
- [27] O'Brien KL, Nohynek H. Report from a WHO Working Group: standard method for detecting upper respiratory carriage of *Streptococcus pneumoniae*. *Pediatr Infect Dis J* 2003;22:e1–11.
- [28] Roca A, Oluwalana C, Camara B, Bojang A, Burr S, Davis TM, et al. Prevention of bacterial infections in the newborn by pre-delivery administration of azithromycin: study protocol of a randomized efficacy trial. *BMC Pregnancy Childbirth* 2015;15:302.
- [29] Austrian R. The Quellung reaction, a neglected microbiologic technique. *Mt Sinai J Med* 1976;43:699–709.
- [30] Greenland S. Invited commentary: variable selection versus shrinkage in the control of multiple confounders. *Am J Epidemiol* 2008;167:523–9.
- [31] Newson RB. Attributable and unattributable risks and fractions and other scenario comparisons. *Stata J* 2013;13:672–98.
- [32] Usuf E, Bojang A, Hill PC, Bottomley C, Greenwood B, Roca A. Nasopharyngeal colonization of Gambian infants by *Staphylococcus aureus* and *Streptococcus pneumoniae* before the introduction of pneumococcal conjugate vaccines. *New Microbes New Infect* 2016;10:13–8.
- [33] Darboe MK, Fulford AJ, Secka O, Prentice AM. The dynamics of nasopharyngeal *Streptococcus pneumoniae* carriage among rural Gambian mother–infant pairs. *BMC Infect Dis* 2010;10:195.
- [34] Kaur R, Casey JR, Pichichero ME. Emerging *Streptococcus pneumoniae* strains colonizing the nasopharynx in children after 13-valent pneumococcal conjugate vaccination in comparison to the 7-valent era, 2006–2015. *Pediatr Infect Dis J* 2016;35:901–6.
- [35] Nzenze SA, von Gottberg A, Shiri T, van Niekerk N, de Gouveia L, Violari A, et al. Temporal changes in pneumococcal colonization in HIV-infected and HIV-uninfected mother–child pairs following transitioning from 7-valent to 13-valent pneumococcal conjugate vaccine, Soweto, South Africa. *J Infect Dis* 2015;212:1082–92.
- [36] Bottomley C, Roca A, Hill PC, Greenwood B, Isham V. A mathematical model of serotype replacement in pneumococcal carriage following vaccination. *J R Soc Interface* 2013;10:20130786.
- [37] Roca A, Dione MM, Bojang A, Townend J, Egere U, Darboe O, et al. Nasopharyngeal carriage of pneumococci four years after community-wide vaccination with PCV-7 in The Gambia: long-term evaluation of a cluster randomized trial. *PLoS One* 2013;8:e72198.
- [38] Usuf E, Badji H, Bojang A, Jarju S, Ikumapayi UN, Antonio M, et al. Pneumococcal carriage in rural Gambia prior to the introduction of pneumococcal conjugate vaccine: a population-based survey. *Trop Med Int Health* 2015;20:871–9.
- [39] Heinsbroek E, Tafatatha T, Chisambo C, Phiri A, Mwiba O, Ngwira B, et al. Pneumococcal acquisition among infants exposed to HIV in rural Malawi: a longitudinal household study. *Am J Epidemiol* 2016;183:70–8.
- [40] Turner P, Turner C, Jankhot A, Helen N, Lee SJ, Day NP, et al. A longitudinal study of *Streptococcus pneumoniae* carriage in a cohort of infants and their mothers on the Thailand–Myanmar border. *PLoS One* 2012;7:e38271.
- [41] Tigoi CC, Gatakaa H, Karani A, Mugo D, Kungu S, Wanjiru E, et al. Rates of acquisition of pneumococcal colonization and transmission probabilities, by serotype, among newborn infants in Kilifi District, Kenya. *Clin Infect Dis* 2012;55:180–8.

- [42] Nunes MC, Shiri T, van Niekerk N, Cutland CL, Groome MJ, Koen A, et al. Acquisition of *Streptococcus pneumoniae* in pneumococcal conjugate vaccine-naïve South African children and their mothers. *Pediatr Infect Dis J* 2013;32:e192–205.
- [43] Bojang A, Jafali J, Egere UE, Hill PC, Antonio M, Jeffries D, et al. Seasonality of pneumococcal nasopharyngeal carriage in rural gambia determined within the context of a cluster randomized pneumococcal vaccine trial. *PLoS One* 2015;10:e0129649.
- [44] Mackenzie GA, Leach AJ, Carapetis JR, Fisher J, Morris PS. Epidemiology of nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: cross-sectional surveys in a population with high rates of pneumococcal disease. *BMC Infect Dis* 2010;10:304.
- [45] Turner P, Hinds J, Turner C, Jankhot A, Gould K, Bentley SD, et al. Improved detection of nasopharyngeal cocolonization by multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping by microarray. *J Clin Microbiol* 2011;49:1784–9.